Assessment of the Safety and Effectiveness of Stem Cell Treatments for Dry Eye Syndrome Associated with Sjögren’s Syndrome: A Systematic Review and Meta-Analysis - Summary - MDSpire
Advertisement
Assessment of the Safety and Effectiveness of Stem Cell Treatments for Dry Eye Syndrome Associated with Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
To systematically quantify the efficacy and safety of stem cell-based therapies in treating dry eye syndrome caused by Sjögren’s syndrome, considering the current lack of clinical approval.
Key Findings:
Stem cell therapy significantly reduced OSDI scores by -15.10 (95% CI: -18.65, -11.56; P < 0.00001).
NIKBUT first scores increased by 3.26 points post-treatment (95% CI: 2.17, 4.34; P < 0.0001).
Schirmer test scores improved by 3.87 (95% CI: 1.93, 5.81; P < 0.0001).
Adverse events included injection pain (14%), ocular discomfort (16%), and periorbital edema (14%).
Interpretation:
Stem cell therapy shows promise in improving symptoms of dry eye syndrome associated with Sjögren’s syndrome, but potential adverse events necessitate careful consideration and monitoring.
Limitations:
Limited number of studies (five) and patients (114) included in the meta-analysis, which may affect the generalizability of the findings.
Short follow-up duration for assessing long-term safety and efficacy.
Conclusion:
Stem cell therapy effectively reduces symptoms of dry eye syndrome due to Sjögren’s syndrome, but risks must be weighed against benefits, requiring close monitoring during treatment and further research to validate these findings.
